Abstract
OP8 A New Complement Inhibitor: Impact of Ravulizumab on Eculizumab and Future Biosimilars Use, and Role of Paris Public Hospitals (AP-HP)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have